Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Lupin arm has received tentative FDA approval for anti bacterial drug

The US-based subsidiary of Lupin, Gavis Pharmaceuticals has received tentative approval from the USFDA for Azithromycin for oral suspension, an anti-bacterial drug, in the American market.

Lupin has said in a BSE filing that Gavis has received tentative approval for its Azithromycin for oral suspension USP from the United States Food and Drug Administration (FDA).

The company’s product is a generic version of Pfizer Inc’s Zithromax and has been indicated for mild to moderate infections caused by bacteria.

Read EquityPandit’s Technical Analysis on Nifty Pharma 

Get Daily Prediction & Stocks Tips On Your Mobile